Items where authors include "Vasudev, NS"

Article

Wah, TM, Zhong, J, Wilson, M et al. (2 more authors) (2021) An Exploratory Analysis of Changes in Circulating Plasma Protein Profiles Following Image-Guided Ablation of Renal Tumours Provides Evidence for Effects on Multiple Biological Processes. Cancers, 13 (23). 6037. ISSN 2072-6694

Zhong, J orcid.org/0000-0001-5325-3739, Palkhi, E, Buckley, DL orcid.org/0000-0001-6659-8365 et al. (7 more authors) (2021) Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics, 11 (7). 1302. ISSN 2075-4418

Hornigold, N, Dunn, KR, Craven, RA et al. (22 more authors) (2020) Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. British Journal of Cancer, 123 (1). pp. 137-147. ISSN 0007-0920

Vasudev, NS orcid.org/0000-0001-8470-7481, Wilson, M, Stewart, GD et al. (13 more authors) (2020) Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open, 10 (5). e035938. ISSN 2044-6055

Cheeseman, S, Thompson, M, Sopwith, W et al. (18 more authors) (2020) Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre. Frontiers in Oncology, 10. 167.

Vasudev, NS orcid.org/0000-0001-8470-7481, Selby, PJ and Banks, RE orcid.org/0000-0002-0042-8715 (2020) AUTHOR REPLY. Urology, 136. p. 168. ISSN 0090-4295

Vasudev, NS orcid.org/0000-0001-8470-7481, Hutchinson, M, Trainor, S et al. (17 more authors) (2020) UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. Urology, 136. pp. 162-168. ISSN 0090-4295

Buckley, HL orcid.org/0000-0002-9829-5817, Collinson, FJ, Ainsworth, G et al. (15 more authors) (2019) PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 19. ARTN: 1102. ISSN 1471-2407

Collinson, F, Brown, S, Buckley, H orcid.org/0000-0002-9829-5817 et al. (11 more authors) (2018) PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Annals of Oncology (Part of special issue:Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany), 29 (8). viii331-viii331. ISSN 0923-7534

Cheung, SY, Henrot, M, Al-Saad, M et al. (17 more authors) (2018) TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A. Oncotarget, 9 (51). pp. 29634-29643. ISSN 1949-2553

Karimzadeh, M, Jandaghi, P, Papadakis, AI et al. (11 more authors) (2018) Aberration hubs in protein interaction networks highlight actionable targets in cancer. Oncotarget, 9 (38). pp. 25166-25180. ISSN 1949-2553

Robinson, SP, Boult, JKR, Vasudev, NS orcid.org/0000-0001-8470-7481 et al. (1 more author) (2017) Monitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI. Cancer Research, 77 (15). pp. 4127-4134. ISSN 0008-5472

Arseneault, M, Monlong, J, Vasudev, NS orcid.org/0000-0001-8470-7481 et al. (25 more authors) (2017) Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma. Scientific Reports, 7. 44876. ISSN 2045-2322

Bridgeman, VL, Vermeulen, PB, Foo, S et al. (19 more authors) (2017) Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. The Journal of Pathology, 241 (3). pp. 362-374. ISSN 0022-3417

Ludlow, MJ, Gaunt, HJ, Rubaiy, HN orcid.org/0000-0002-1489-5576 et al. (5 more authors) (2017) (-)-Englerin A-evoked Cytotoxicity is Mediated by Na+ Influx and Counteracted by Na+/K+-ATPase. Journal of Biological Chemistry, 292 (2). pp. 723-731. ISSN 0021-9258

Gaunt, HJ, Vasudev, NS orcid.org/0000-0001-8470-7481 and Beech, DJ (2016) Transient receptor potential canonical 4 and 5 proteins as targets in cancer therapeutics. European Biophysics Journal, 45 (7). pp. 611-620. ISSN 0175-7571

Scelo, G, Hofman, JN, Banks, RE et al. (26 more authors) (2016) International cancer seminars: a focus on kidney cancer. Annals of Oncology, 27 (8). pp. 1365-1366. ISSN 0923-7534

Hayward, JS, Makinde, O and Vasudev, NS orcid.org/0000-0001-8470-7481 (2016) Letters of condolence: assessing attitudes and variability in practice amongst oncologists and palliative care doctors in Yorkshire. ecancermedicalscience, 10. 642. ISSN 1754-6605

Bridgeman, VL, Wan, E, Foo, S et al. (12 more authors) (2016) Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 15 (1). pp. 172-183. ISSN 1535-7163

Akbulut, Y, Gaunt, HJ, Muraki, K et al. (12 more authors) (2015) (−)-Englerin A is a Potent and Selective Activator of TRPC4 and TRPC5 Calcium Channels. Angewandte Chemie International Edition, 54 (12). pp. 3787-3791. ISSN 1433-7851

Vasudev, NS orcid.org/0000-0001-8470-7481 and Reynolds, AR (2014) Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis, 17 (3). pp. 471-494. ISSN 0969-6970

Monograph

Selby, PJ, Banks, RE orcid.org/0000-0002-0042-8715, Gregory, W orcid.org/0000-0003-2641-8416 et al. (50 more authors) (2018) Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Report. NIHR Journals Library , Southampton, UK. ISSN 2050-4322

Conference or Workshop Item

Vasudev, NS orcid.org/0000-0001-8470-7481, Ainsworth, G, Brown, S orcid.org/0000-0002-7975-7537 et al. (17 more authors) (2021) LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). In: ESMO Congress 2021, 16-21 Sep 2021, Virtual.